Teva, the world's top generic drug maker, will likely take control of Taiyo by purchasing a majority stake from the founding family and other shareholders, it said.
Teva started a Japanese unit in 2005 and formed a generic drug joint venture, Teva-Kowa Pharma, with midtier Japanese pharmaceutical firm Kowa in 2008.
It appears that Teva is looking to mainly use Taiyo for production and Teva-Kowa for sales, the Nikkei said.
The roughly 800 billion yen ($9.85 billion) Japanese generic drug market accounts for about 20% of the overall domestic pharmaceutical market, considerably lower than the 50 percent or higher in the US and Europe, the Nikkei said.
- Follow Ynetnews on Facebook